Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters

Chattopadhyay, Nabanita Roy; Chatterjee, Koustav; Banerjee, Antara; Choudhuri, Tathagata

doi:10.1007/s13337-020-00631-w

Cited by 6 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Artesunate did not interact with S protein RBD or RdRp. Also, artemether interacted with NC protein, helicase protein, nsp10, and nsp15 [50] . The corresponding author of this study was contacted to clarify some aspects of the methodology of this study and parameters of data interpretation.…”

Section: Resultsmentioning

confidence: 99%

“…Other antimalarials: CQ, –6.2 kcal/mol; HCQ, –5.2 kcal/mol; mefloquine, –6.7 kcal/mol; pyrimethamine, –5.8 kcal/mol. Chattopadhyay et al, 2020 [50] FDA-approved drugs and chemicals were screened and tested against several SARS-CoV-2-host target proteins such as RdRp, helicase protein, NC, S protein RBD, E protein, nsp10, nsp14, and nsp15. Virtual screening and molecular docking.…”

Section: Resultsmentioning

confidence: 99%

“…In another study, the binding capacity of FDA-approved drugs and chemicals against a series of SARS-CoV-2/host proteins such as RdRp, helicase protein, nucleocapsid (NC or N) protein, S protein RBD, E protein, nsp10, nsp14, and nsp15 were examined [50] . The screened drugs included artesunate, artemether, antimalarial pharmaceutical drugs (CQ, quinine, primaquine, amodiaquine, mefloquine, and proguanil), the antiviral drugs galidesivir, remdesivir, pirodavir, and others.…”

Section: Resultsmentioning

confidence: 99%

“…The screened drugs included artesunate, artemether, antimalarial pharmaceutical drugs (CQ, quinine, primaquine, amodiaquine, mefloquine, and proguanil), the antiviral drugs galidesivir, remdesivir, pirodavir, and others. Artesunate exhibited binding activity with E protein, helicase protein, nucleocapsid (NC) protein, and with the non-structural proteins nsp10, nsp14, and nsp15 [50] . Artesunate did not interact with S protein RBD or RdRp.…”

Section: Resultsmentioning

confidence: 99%

“…The corresponding author of this study was contacted to clarify some aspects of the methodology of this study and parameters of data interpretation. In this case, artesunate was classified as “may be chosen” and artemether was “not chosen” as SARS-CoV-2/host inhibitors even though all binding scores were ≤ –7.0 kcal/mol [50] . From these two, the best binding score was attained by the artesunate-N protein interaction (–8.8 kcal/mol).…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment

Fuzimoto

2021

Journal of Integrative Medicine

View full text Add to dashboard Cite

Artemisia annua and its phytocompounds have a rich history in the research and treatment of malaria, rheumatoid arthritis, systemic lupus erythematosus, and other diseases. Currently, the World Health Organization recommends artemisinin-based combination therapy as the first-line treatment for multi-drug-resistant malaria. Due to the various research articles on the use of antimalarial drugs to treat coronaviruses, a question is raised: do A. annua and its compounds provide anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) properties. PubMed/MEDLINE, Scopus, and Google Scholar were searched for peer-reviewed articles that investigated the antiviral effects and mechanisms of A. annua and its phytochemicals against SARS-CoVs. Particularly, articles that studied the herb’s role in inhibiting the coronavirus-host proteins were favored. Nineteen studies were retrieved. From these, fourteen in silico molecular docking studies demonstrated potential inhibitory properties of artemisinins against coronavirus-host proteins, including 3CL PRO , S protein, N protein, E protein, cathepsin-L, helicase protein, nsp3, nsp10, nsp14, nsp15, and GRP78 receptor. Collectively, A. annua constituents may impede the SARS-CoV-2 attachment, membrane fusion, and internalization into the host cells, and hinder the viral replication and transcription process. This is the first comprehensive overview of the application of compounds from A. annua against SARS-CoV-2/coronavirus disease 2019 (COVID-19) describing all target proteins. A. annua ’s biological properties, the signaling pathways implicated in the COVID-19, and the advantages and disadvantages for repurposing of A. annua compounds are discussed. The combination of A. annua ’s biological properties, action on different signaling pathways and target proteins, and a multi-drug combined-therapy approach may synergistically inhibit SARS-CoV-2 and assist in the COVID-19 treatment. Also, A. annua may modulate the host immune response to better fight the infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment

Fuzimoto

2021

Journal of Integrative Medicine

View full text Add to dashboard Cite

show abstract

Integrating heterogeneous data to facilitate COVID-19 drug repurposing

Santamaría

Uzquiano

Carro

et al. 2022

Drug Discovery Today

View full text Add to dashboard Cite

In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-related genes and COVID-19 symptoms with drugs that directly target these gene products, that target the symptoms or that treat diseases that are symptomatically or genetically similar to COVID-19. The intersection of the five information paths results in a list of 13 drugs that we suggest as potential candidates against COVID-19. In addition, we have found information in published studies and in clinical trials that support the therapeutic potential of the drugs in our final list.

show abstract

Molecular insights into the interaction of eighteen different variants of SARS-CoV-2 spike proteins with sixteen therapeutically important phytocompounds: in silico approach

Batra

Srinivasan

Gopalakrishnan

et al. 2023

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters

Cited by 6 publications

References 36 publications

An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment

An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment

Integrating heterogeneous data to facilitate COVID-19 drug repurposing

Molecular insights into the interaction of eighteen different variants of SARS-CoV-2 spike proteins with sixteen therapeutically important phytocompounds: in silico approach

Contact Info

Product

Resources

About